Medical Tech Stock SINTX Technologies, Inc. (NASDAQ: SINT) Big Winner for Day Traders on Patent News
September 9, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including medical technology stocks reports on trading and news for SINTX Technologies, Inc. (NASDAQ: SINT) a leading innovator in ceramic manufacturing.
The stock made the NASDAQ top percentage gainer in today's trading session, currently trading at $5.31, up 2.49, gaining 88.07% on volume of over 57 Million shares. The stock had a morning high of $6.98 as of this report.
SINTX today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 17/634,141 entitled "Methods of Surface Functionalization of Zirconia-Toughed Alumina with Silicon Nitride Ceramic." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
This patent allowance underscores the Company's commitment to advancing the development of advanced ceramic for biomaterial applications, protecting its intellectual property, and delivering innovative solutions to its customers.
The patent covers novel methods of bonding bioactive silicon nitride or mixtures of silicon nitride and bioactive glass to zirconia-toughened alumina (ZTA) and similar material surfaces. This invention is designed to impart silicon nitride's beneficial biomedical properties, namely improved osseointegration and resistance to bacterial colonization, to relatively biologically inert ZTA substrates, positioning SINTX at the forefront of medical device biomaterial manufacturing.
"Our patent allowance marks a significant milestone for our patent portfolio and the development of proprietary biomaterials" said Eric K. Olson, President and CEO of SINTX. "This innovation reinforces our leadership in innovative medical device platforms and demonstrates our ongoing commitment to developing cutting-edge solutions, transformative technologies, and development of commercial products that benefit our customers and the broader market."
SINTX, currently the only FDA-registered producer of implantable silicon nitride, in addition to its monolithic ceramic implantable device offerings, has recently developed a particulate form of its silicon nitride that can be used in composites and coatings. When compounded with or applied to the surface of conventional inert biomaterials, silicon nitride's improved osseointegration and resistance to bacterial colonization can be conferred to the resulting device. Another benefit of the coating method is that it allows for potential refinishing of existing devices to upgrade their functionality. Other filings in progress protect similar approaches to applying silicon nitride to metallic and polymeric substrates as part of SINTX's broader strategy of expanding the applications where silicon nitride's benefits can be realized.
With this allowance, SINTX continues to build a robust intellectual property portfolio, which now includes 16 issued patents in the United States with an additional 84 pending patent applications in Worldwide.
Recent news
https://finance.yahoo.com/news/sintx-receives-notice-allowance-united-120000224.html
Research more Biotech and medical technology stocks with Investorideas.com free stock directory
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: More disclaimer and disclosure info https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on X @investorideas @stocknewsbites
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Sign up for free stock news alerts at Investorideas.com
Contact Investorideas.com
800 665 0411
